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RESPONSES TO LETTER





W e are pleased to read the letter fromMiller and Doherty and are delighted
that our study on lymphadenectomy in
adrenocortical carcinoma (ACC) gives rise
to an intensive discussion. The German ACC
Registry is a comprehensive database and is
maintained prospectively since 2003. How-
ever, relevant data for the current study were
retrieved retrospectively from pathology re-
ports, surgical protocols, and patient charts.
As indicated in our publication, such data are
limited in terms of their explanatory power
and should be interpreted with some caution.1
Nevertheless, regarding the issue of lym-
phadenectomy in ACC, a higher level of evi-
dence (eg, prospective data) has not yet been
published and can probably not be expected
in the near future.
It is plausible to assume that a (early)
lymphatic invasion indicates aggressive tu-
mor biology and is associated with a poor
prognosis. This is clearly demonstrated for
lymph node–positive patients, not only in our
current series but also in other series.2–4 As
suggested by Miller and Doherty, we per-
formed an analysis including all patients for
which both the lymph node status and Ki67
were available. This analysis showed that
lymph node–positive patients (n = 14) had
significantly higher Ki67 values (median =
20% vs 10%, P = 0.018) than patients without
involved lymph nodes (n = 144). However,
we cannot reliably answer the question on in-
tratumoral lymphatic invasion. Because the
included patients were treated in more than
100 institutions in Germany, the pathology
reports were not standardized. Furthermore,
intratumoral lymphatic invasion is not an es-
tablished criterion to evaluate adrenocortical
tumors and was therefore not reported by the
German reference pathologist, Prof Wolfgang
Saeger, who reviewed about half of the sam-
ples. Thus, information on intratumoral lym-
phatic invasion was available for only 78 pa-
tients and an invasion was present in only 8
patients, precluding a meaningful analysis.
In our study, we intentionally decided
not to refer to subgroup analysis in terms of
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tumor recurrence, which would have resulted
in small patient numbers (in each subgroup)
for this rare condition. As requested by Miller
and Doherty, we have now performed this
analysis. It became apparent that the rate of
local recurrence was comparable for patients
who had undergone lymph node dissection
(LND patients) and those who had not un-
dergone lymph node dissection (noLND pa-
tients, 68.7% vs. 65.5%). However, LND pa-
tients experienced local recurrence somewhat
later than noLND patients (19.6 months vs
15.5 months, P = 0.08). Taking into account
a significantly higher rate of locally advanced
tumors in the LND group at primary diagno-
sis and the reduced sample sizes, we inter-
pret these results as a trend to a better local
tumor control in patients undergoing locore-
gional lymph node dissection. Nevertheless,
further studies are necessary to better define
subgroups of patients who specifically benefit
from such an approach.
We are well aware that our definition
of “regional lymphadenectomy” according to
the total number of excised lymph nodes is
arbitrarily chosen and prone to some criti-
cism. We also agree that the number of re-
ported nodes strongly depends on the com-
pleteness of the pathological examination. We
can exclude neither the possibility that some
of our LND patients underwent lymph node
dissection only by chance nor the fact that in
some cases the reported lymph nodes came
from outside of the lymph node basin of the
adrenal gland or the demarcated area of Fig-
ure 5 of our publication.1 This scenario might
particularly apply for those patients who un-
derwent a multivisceral resection. However,
surgeons and pathologists are confronted with
such an “inaccuracy” in lymph node evalua-
tion in most specimens after extended tumor
surgery, not only in ACC. The fact that our
patients underwent surgery in multiple insti-
tutions and the operative data was retrieved
retrospectively precludes a more precise def-
inition of regional lymphadenectomy in our
series. Obviously, much more work is needed
before the quality of oncological surgery in
terms of the total number of excised lymph
nodes (and fields of dissection) can be de-
fined for ACC. However, besides the total
number of excised nodes (which is influenced
by the resection of adjacent organs), the defi-
nition of lymphadenectomy in our series was
also based on the efforts of the surgeon to
perform a locoregional lymph node dissec-
tion in the periadrenal region. Provided that
only those patients who underwent an “in-
tended” locoregional lymphadenectomy ac-
cording to the surgical protocol and presented
5 or more lymph nodes in the pathology re-
port were considered as LND patients in our
series, we strongly assume that in the major-
ity of cases the reported lymph nodes came
from the locoregional lymph node basin of the
adrenal gland. However, we acknowledge that
a “more precise definition of regional lym-
phadenectomy,” as requested by Miller and
Doherty, requires the results of prospective
trials with standardized surgery and patholog-
ical workup. Therefore, the proposed fields
for lymphadenectomy (see Figure 5 of our
publication1), which are based on the pattern
of recurrence in ACC patients,5 should be re-
garded as plausible suggestions.
In summary, our study on lymph node
dissection in ACC covered an issue that has
not been addressed before. We are aware that
the retrospective design of our study is prone
to some bias. Moreover, a single study cannot
cover such an approach exhaustively and, in-
evitably, questions will remain until prospec-
tive data are available. We, therefore, propose
to initiate a study with the surgical colleagues
from Ann Arbor and other centers to further
define the role of lymphadenectomy in ACC.
Joachim Reibetanz, MD
Christian Jurowich, MD
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